1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • November 2016
  • -
  • BCC Research
  • -
  • 128 pages

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines.


Use this report to:
- Analyze the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder.
- Explore present and future strategies within the cancer vaccines market.
- Learn about the development of the market, the holdups and the needs of the market.
- Gain an insight in to the classifications and usage of the prophylactic vaccines and therapeutic vaccines.


Highlights
- The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.
- North American market is expected to grow from $1.7 billion in 2016 to nearly $1.9 billion in 2021 at a CAGR of 1.4% from 2016 through 2021.
- European market is expected to grow from $777.4 million in 2016 to $847.3 million at a CAGR of 1.7% from 2016 through 2021.

STUDY OBJECTIVES
According to the World Health Organization, cancer has become the leading cause of death in recent years. Though cancer vaccines presently represent a minor share of the oncology industry, they are expected to be one of the most profitable segments for pharmaceutical companies over the forecast period. Most cancer vaccines work by improving a person’s immune system, allowing it to attack cancer cells, and thus virus-induced cancers can be prevented using vaccines. BCC Research’s goal in conducting this study is to provide an overview of the current and future dynamics of the global market for various cancer vaccines.


This report explores present and future strategies within the cancer vaccines market, which includes prophylactic vaccines and therapeutic vaccines. The development of the market, the holdups and the needs of the market are discussed in this report. The classifications and usage of these vaccines are also discussed in this report. A detailed analysis of the cancer vaccines industry has been conducted and the revenues broken down by three regions. The sales figures are estimated for the five-year period from 2016 through 2021. Market by application of various cancer vaccines are also discussed separately in the report, as well as significant patents and their allotments in each category.



REASONS FOR DOING THIS STUDY
Cancer vaccines are an important part of the biomedical industry. The sharp rise in cancer throughout the world is a consequence of combined genetic, social and environmental factors. Thus, the need for preventive as well as therapeutic vaccines is increasing progressively. Recently, some of the vaccines that help protect against viral infections have shown promising results to prevent some of these viral-induced cancers. Modern industries have now begun to explore the advantages of cancer vaccines in their productions and processes. Many government initiatives are encouraging researchers to develop cancer immunotherapies.

The nature of the disease, expected increase in demand for cancer vaccines and higher profitability as compared with generic drugs are the growth factors of this market. Acquisition strategies and collaborations by companies are also covered in this report as well as the strengths and weaknesses of each type of vaccine in light of the new technologies, growing competition, and changing customer needs.


CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
This study contributes to the areas of market growth for cancer vaccine manufacturers and users. Genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies, and physicians will find this study to be of interest.



SCOPE OF THE STUDY
The scope of this study entails the global market of cancer vaccines. The report covers the total market of cancer vaccines, which includes two main areas of applications, prophylactic vaccines and therapeutic vaccines. Human papillomavirus (HPV) vaccines and hepatitis B vaccines that indirectly act against cancer are also included in the report.

The report also covers the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder. It is discussed from both a commercial perspective and that of a research and development (R&D) perspective.
BCC Research analyzes each market and its application, regulatory environment, new products and advancements, market projections and market shares. Sales data for the global and regional markets were corroborated for the present and forecasted values via statistical analysis and geographically sales are broken down into North America, Europe and emerging markets. The emerging market covers countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada among others.

Analysis of patents, clinical trials, innovations and opportunities the latest trends in the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.


METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers and users of cancer vaccines. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.


INFORMATION SOURCES
Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of cancer vaccines. Data was gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ANALYSTS’ CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this report is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and she has worked with top companies in India and the U.S.



Some of the other reports Shalini has compiled for BCC Research are:
- Global Markets for Reagents for Chromatography.
- Global Markets for Spectroscopy Equipment.
- Global Markets and Technologies for Advanced Drug Delivery Systems.
- Orthopedic Drugs, Implants and Devices.
- Global Markets for Medical Imaging Reagents and Analysis Equipment.
- Pharmaceutical Regulatory Industry.
- Global Markets for Media, Sera and Reagents in Biotechnology.
- Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging.
- Global Markets for Chiral Technology.
- Autacoids and Related Drugs: Technologies and Global Markets.
- Contraceptives: Technologies and Global Markets.
- Liver Disease Treatments: The Global Market.
- Hormone Replacement Therapies and Other Hormone Therapies: Global Markets.
- Cardiovascular Medicine: Diagnostics, Drugs and Devices.
- Cancer Therapies: Technologies and Global Markets.
- Medical Imaging Reagents and Analysis Equipment.
The lead consultant on this project was Dr. Kapil A. Setia, who holds a doctoral degree in the life sciences. She has a number of research publications to her credit, including her thesis, which received an award for excellence.

Table Of Contents

Cancer Vaccines: Technologies and Global Markets
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 2
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYSTS' CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH
2021 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 10
DEFINITIONS 10
HISTORY OF CANCER AND ITS MANAGEMENT 12
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT 12
CAUSES OF CANCER 14
GENETIC FACTORS 14
LIFESTYLE FACTORS 14
ENVIRONMENTAL FACTORS 14
TYPES OF CANCER-CAUSING GENES 15
IMMUNE SYSTEM AND CANCER 15
CLASSIFICATION OF CANCER 16
CANCER PREVENTION 17
TYPES OF CANCER TREATMENT 17
SURGERY 17
RADIATION THERAPY 18
CHEMOTHERAPY 18
IMMUNOTHERAPY 18
TARGETED THERAPY 18
CANCER VACCINES 19
LIVER CANCER 19
PROSTATE CANCER 21
Radical Retropubic Prostatectomy 21
Laparoscopic Prostatectomy 22
Radical Perineal Prostatectomy 22
Transurethral Resection of the Prostate 22
CERVICAL CANCER 23
CANCER VACCINES PLATFORM 24
Tumor Cell Vaccines 24
Cancer Stem Cell Vaccines 25
Peptide/Protein Vaccines 25
Antigen Vaccines 25
Anti-idiotype Vaccines 25
Heat Shock Protein Vaccines 26
DNA and Vector-Based Vaccines 26
CHAPTER 4 REGULATORY ASPECTS 29
REGULATORY HISTORY OF APPROVED CANCER VACCINES 30
TABLE 2 REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT.
2015 31
RECALLS 31
TABLE 3 PRODUCT RECALLS, DECEMBER 2013 32
ORPHAN DRUG DESIGNATION 32
TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO
JUNE 2016 32
FAST TRACK DESIGNATIONS 33
CHAPTER 5 NEW DEVELOPMENTS 35
PROSTATE CANCER 36
TABLE 5 CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016
(NO.) 36
TABLE 6 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF
JUNE 2016 37
BREAST CANCER 37
TABLE 7 CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.) 38
TABLE 8 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE
2016 38
CERVICAL CANCER 39
TABLE 9 CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016
(NO.) 40
TABLE 10 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF
JUNE 2016 40
LIVER CANCER 41
TABLE 11 CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.) 42
TABLE 12 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE
2016 42
LUNG CANCER 43
TABLE 13 CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.) 43
TABLE 14 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF
JUNE 2016 44
STOMACH CANCER 45
TABLE 15 CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016
(NO.) 45
TABLE 16 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF
JUNE 2016 45
COLORECTAL CANCER 46
TABLE 17 CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016
(NO.) 46
TABLE 18 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF
JUNE 2016 47
ESOPHAGEAL CANCER 47
TABLE 19 CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016
(NO.) 48
TABLE 20 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF
JUNE 2016 48
CHAPTER 6 MARKET ANALYSIS 50
MARKET BY TYPE 50
MARKET OVERVIEW 51
MARKET REVENUE 54
TABLE 21 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 ($
MILLIONS) 55
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 ($
MILLIONS) 55
MARKET SHARES 55
TABLE 22 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%) 56
FIGURE 2 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%) 56
MARKET BY REGION 56
MARKET OVERVIEW 57
MARKET REVENUE 58
TABLE 23 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($
MILLIONS) 59
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($
MILLIONS) 59
THERAPEUTIC VACCINES 60
Market Overview 62
Market Revenue 66
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 67
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 67
Market Share 68
TABLE 25 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%) 68
FIGURE 5 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%) 68
PROPHYLACTIC VACCINES 69
Market Overview 70
Market Revenue 73
TABLE 26 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 75
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 75
Market Share 76
TABLE 27 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%) 76
FIGURE 7 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%) 76
CHAPTER 7 INDUSTRY STRUCTURE 79
PROPHYLACTIC CANCER VACCINES 79
MARKET LEADERS 79
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER
VACCINES, 2015 79
MARKET SHARE 79
TABLE 29 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER
VACCINES, 2015 (%) 80
FIGURE 8 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER
VACCINES, 2015 (%) 80
THERAPEUTIC CANCER VACCINES 80
MARKET LEADER 80
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER
VACCINES, 2015 81
MARKET SHARE 81
TABLE 31 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER
VACCINES, 2015 (%) 81
FIGURE 9 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER
VACCINES, 2015 (%) 81
CHAPTER 8 MARKET BY APPLICATION 84
GLOBAL MARKET FOR CANCER VACCINES BY APPLICATION IN VARIOUS
CANCERS 84
MARKET REVENUES 84
TABLE 32 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER,
THROUGH 2021 ($ MILLIONS) 85
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER,
2014-2021 ($ MILLIONS) 85
MARKET SHARE 85
TABLE 33 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%) 86
FIGURE 11 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%) 86
PROSTATE CANCER 86
MARKET OVERVIEW 87
MARKET REVENUE 89
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 89
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 89
LIVER CANCER 90
MARKET OVERVIEW 90
MARKET REVENUES 92
TABLE 35 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH
2021 ($ MILLIONS) 93
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021
($ MILLIONS) 93
CERVICAL CANCER VACCINES 94
MARKET OVERVIEW 95
MARKET REVENUES 96
TABLE 36 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION,
THROUGH 2021 ($ MILLIONS) 97
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 97
OTHER VACCINES FOR CANCER 98
MARKET OVERVIEW 98
MARKET REVENUE 99
TABLE 37 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH
2021 ($ MILLIONS) 99
FIGURE 15 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION,
2014-2021 ($ MILLIONS) 99
CHAPTER 9 PATENT ANALYSIS 102
PATENTS BY YEAR 102
TABLE 38 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.) 102
FIGURE 16 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.) 103
PATENTS BY TYPE/CATEGORY 103
TABLE 39 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.) 103
FIGURE 17 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.) 103
PATENTS BY COMPANY 104
TABLE 40 U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.) 104
PATENTS BY COUNTRY 105
TABLE 41 U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.) 105
TABLE 42 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%) 106
FIGURE 18 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%) 106
PATENTS BY ASSIGNEE TYPE 107
TABLE 43 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.) 107
FIGURE 19 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.) 107
CHAPTER 10 CURRENT SITUATION 110
FACTORS AFFECTING CANCER VACCINES 110
INCREASING PREVALENCE OF CANCER 110
AGING POPULATION 111
LIFESTYLE CHANGES 111
APPROVALS FOR ADDITIONAL INDICATIONS 111
COMPETITION 112
INCREASED FUNDING 112
MANUFACTURERS' STRATEGIES 112
CHALLENGES IN CANCER VACCINE MARKET 114
CHAPTER 11 COMPANY PROFILES 116
ADAMIS PHARMACEUTICALS CORP. 116
ADURO BIOTECH INC. 116
ADVANTAGENE INC. 117
ADVAXIS INC. 118
ALPHAVAX INC. 118
ALTOR BIOSCIENCE CORP. 119
ANTIGEN EXPRESS INC. 120
BAVARIAN NORDIC A/S 120
BELLICUM PHARMACEUTICALS 121
BIOVEST INTERNATIONAL INC. 121
CASCADIAN THERAPEUTICS INC. 122
CELLDEX THERAPEUTICS 123
CUREVAC AG 123
DENDREON CORP. 124
EMD SERONO 124
GALENA BIOPHARMA INC. 125
GENEXINE INC. 125
GLAXOSMITHKLINE 126
GLOBEIMMUNE INC. 126
GRADALIS 127
HEAT BIOLOGICS INC. 127
IMMUNE CELL THERAPY INC. (ICT) 128
IMMUNICUM AB 128
IMMUNOVATIVE THERAPIES LTD. 129
INOVIO PHARMACEUTICALS 129
ISA PHARMACEUTICALS B.V. 130
GEMVAX and KAEL CO. LTD. 130
MERCK andCO. 131
NEWLINK GENETICS CORP. 131
NOVARX CORP. 132
ONCOVIR INC. 132
OXFORD BIOMEDICA PLC 133
SOTIO AS 133
UBIVAC LLC 134
VICAL INC. 134
VACCINOGEN INC. 135
VAXON BIOTECH 135
CHAPTER 12 ABBREVIATIONS 138

LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 7
TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT 12
TABLE 2 REGULATORY APPROVALS OF CANCER VACCINES, JUNE 2006 TO OCT. 2015 31
TABLE 3 PRODUCT RECALLS, DECEMBER 2013 32
TABLE 4 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED, JAN. 2012 TO JUNE 2016 32
TABLE 5 CLINICAL TRIALS ON PROSTATE CANCER VACCINES, AS OF JUNE 2016 (NO.) 36
TABLE 6 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 37
TABLE 7 CLINICAL TRIALS ON BREAST CANCER VACCINES, AS OF JUNE 2016 (NO.) 38
TABLE 8 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 38
TABLE 9 CLINICAL TRIALS ON CERVICAL CANCER VACCINES, AS OF JUNE 2016 (NO.) 40
TABLE 10 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 40
TABLE 11 CLINICAL TRIALS ON LIVER CANCER VACCINES, AS OF JUNE 2016 (NO.) 42
TABLE 12 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 42
TABLE 13 CLINICAL TRIALS ON LUNG CANCER VACCINES, AS OF JUNE 2016 (NO.) 43
TABLE 14 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER, AS OF JUNE 2016 44
TABLE 15 CLINICAL TRIALS ON STOMACH CANCER VACCINES, AS OF JUNE 2016 (NO.) 45
TABLE 16 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 45
TABLE 17 CLINICAL TRIALS ON COLORECTAL CANCER VACCINES, AS OF JUNE 2016 (NO.) 46
TABLE 18 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 47
TABLE 19 CLINICAL TRIALS ON ESOPHAGEAL CANCER VACCINES, AS OF JUNE 2016 (NO.) 48
TABLE 20 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT, AS OF JUNE 2016 48
TABLE 21 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS) 55
TABLE 22 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%) 56
TABLE 23 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 59
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 67
TABLE 25 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%) 68
TABLE 26 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 75
TABLE 27 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%) 76
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2015 79
TABLE 29 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%) 80
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2015 81
TABLE 31 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%) 81
TABLE 32 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2021 ($ MILLIONS) 85
TABLE 33 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%) 86
TABLE 24 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 89
TABLE 35 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 93
TABLE 36 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 97
TABLE 37 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 99
TABLE 38 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.) 102
TABLE 39 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.) 103
TABLE 40 U.S. PATENTS BY COMPANY, 2012 TO JUNE 2016 (NO.) 104
TABLE 41 U.S. PATENTS BY COUNTRY, 2012 TO JUNE 2016 (NO.) 105
TABLE 42 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (NO./%) 106
TABLE 43 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.) 107

LIST OF FIGURES
FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 8
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 55
FIGURE 2 MARKET SHARE OF CANCER VACCINES BY TYPE, 2015 (%) 56
FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 59
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 67
FIGURE 5 MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2015 (%) 68
FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 75
FIGURE 7 PROPHYLACTIC VACCINE MARKET SHARES BY REGION, 2015 (%) 76
FIGURE 8 MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2015 (%) 80
FIGURE 9 MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2015 (%) 81
FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2014-2021 ($ MILLIONS) 85
FIGURE 11 CANCER VACCINE MARKET SHARES BY TYPE OF CANCER, 2015 (%) 86
FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 89
FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 93
FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 97
FIGURE 15 GLOBAL MARKET FOR OTHER CANCER VACCINES BY REGION, 2014-2021 ($ MILLIONS) 99
FIGURE 16 U.S. PATENTS BY YEAR, 2012 TO JUNE 2016 (NO.) 103
FIGURE 17 U.S. PATENTS BY CATEGORY, 2012 TO JUNE 2016 (NO.) 103
FIGURE 18 U.S. PATENT SHARES BY COUNTRY, 2012 TO JUNE 2016 (%) 106
FIGURE 19 U.S. PATENTS BY ASSIGNEE TYPE, JAN. 2012 TO JUNE 2016 (NO.) 107

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...

Vaccines Market by Technology, Disease Indication, End User & Type - Forecasts to 2021

Vaccines Market by Technology, Disease Indication, End User & Type - Forecasts to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The vaccines market is expected to reach USD 48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3%. The global vaccines market is segmented based on technology, type, disease indication, ...

Global Veterinary Vaccines Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Vaccine Industry in Canada

  • December 2016
    6 pages
  • Vaccine  

  • Canada  

View report >

Influenza Statistics in the US

  • November 2016
    7 pages
  • Influenza  

    Influenza Vacci...  

    Vaccine  

  • United States  

View report >

Global Therapy Market

12 days ago

Global Vaccine Supply

18 days ago

Related Market Segments :

Vaccine
Cancer Vaccine

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.